Pharmacovigilance Requirements in Brazil

Clinical Trials in: Mexico, Argentina, Colombia and Brazil.

Locally-Based, Full Service CRO

Contact us today to learn more.

+ 0
Sites Throughout LATAM
+ 200
Patients in our network
+ 0
Conducted Studies
0 %
Lost-to-Follow Up rate
As a leading CRO in LATAM, we specialize in supporting clinical trials throughout the region. Our extensive experience and broad network of clinical sites enable us to execute trials with speed and efficiency, ensuring high patient recruitment and retention rates.

Pharmacovigilance Requirements in Brazil

Pharmacovigilance Requirements in Brazil – CRO Partner

Pharmacovigilance, the science and activities related to detecting, assessing, understanding, and preventing adverse effects or any other drug-related issues, is paramount for ensuring the safety of pharmaceutical products. In Brazil, like in many countries, pharmacovigilance plays a crucial role in maintaining public health by monitoring and addressing potential safety concerns associated with drugs.

This blog dives into the pharmacovigilance requirements in Brazil, shedding light on the regulatory framework, reporting obligations, and the importance of effective pharmacovigilance practices.

Regulatory Framework

In Brazil, the National Health Surveillance Agency (Agência Nacional de Vigilância Sanitária, ANVISA) serves as the regulatory authority responsible for overseeing pharmacovigilance activities. ANVISA establishes the guidelines and regulations that pharmaceutical companies, marketing authorization holders, and healthcare professionals must adhere to, ensuring the continued safety and efficacy of pharmaceutical products on the market.

Key Pharmacovigilance Activities

  1. Adverse Event Reporting: A fundamental pharmacovigilance requirement in Brazil is the reporting of adverse events to ANVISA. Marketing authorization holders, pharmaceutical companies, and healthcare professionals are obligated to promptly report any unexpected or severe adverse reactions that occur within the country’s borders. These reports are crucial for assessing a product’s safety profile and making informed regulatory decisions.
  2. Periodic Safety Updates: Marketing authorization holders are also required to submit Periodic Safety Update Reports (PSURs) to ANVISA. These reports provide a comprehensive overview of a drug’s safety profile, including emerging safety concerns, changes to product information, and summaries of adverse events reported over defined time periods.
  3. Risk Management Plans (RMPs): For certain high-risk drugs, ANVISA may mandate the submission of Risk Management Plans. These plans outline strategies and measures for identifying, assessing, and managing the risks associated with the drug. RMPs are particularly relevant for drugs with complex safety profiles or those intended for specific patient populations.
  4. Signal Detection and Evaluation: ANVISA conducts signal detection and evaluation activities to identify potential safety signals linked to marketed drugs. By analyzing data from various sources, including adverse event reports and scientific literature, ANVISA can detect emerging safety concerns that warrant further investigation.

Communication of Safety Information: Marketing authorization holders are responsible for communicating updated safety information to healthcare professionals and patients. This includes updating product labeling and package inserts to reflect new safety findings or changes in the risk-benefit profile of the drug.

Pharmacovigilance Requirements in Brazil

Pharmacovigilance Requirements in Brazil

Pharmacovigilance Requirements in Brazil

Importance of Effective Pharmacovigilance

Effective pharmacovigilance practices in Brazil serve a multitude of critical purposes:

  1. Patient Safety: The foremost objective of pharmacovigilance is to ensure patient safety by swiftly identifying and addressing adverse effects or safety concerns associated with pharmaceutical products. This commitment to patient well-being fosters trust in the healthcare system.
  2. Regulatory Compliance: Adhering to pharmacovigilance requirements is imperative for regulatory compliance. Neglecting to report adverse events or provide timely safety updates can lead to regulatory actions, including product recalls or the suspension of marketing authorization.
  3. Continuous Benefit-Risk Assessment: Pharmacovigilance enables an ongoing assessment of the balance between a drug’s benefits and risks. This information aids in informed decisions about the continued marketing and usage of pharmaceutical products.
  4. Global Collaboration: Adverse events and safety concerns extend beyond national boundaries. Effective pharmacovigilance practices facilitate collaboration and information sharing with international regulatory bodies, contributing to a comprehensive understanding of drug safety profiles.


Pharmacovigilance stands as a pillar of drug safety and public health in Brazil, safeguarding patient well-being and ensuring the integrity of pharmaceutical products. The regulatory framework established by ANVISA outlines clear guidelines for adverse event reporting, safety updates, and risk management strategies.

Adhering to these requirements not only upholds patient health but also ensures regulatory compliance and maintains the standards of the pharmaceutical industry. As pharmacovigilance continues to evolve, its unwavering focus on safety remains pivotal to Brazil’s healthcare landscape and the enhancement of patients’ lives.

Pharmacovigilance Requirements in Brazil

Source: Duke Clinical Research Institute

Welcome to Cohortias!

of Latin America

Simplify Your Clinical Trials with Our Expert Infrastructure in Latin America

Say goodbye to the complex, costly, and disorganized process of conducting clinical trials. Our infrastructure in Latin America streamlines the launch of studies and ensures adherence to international standards. Schedule a call with us today to discover the path to simplified clinical research in Latin America.

Pharmacovigilance Requirements in Brazil

Explore What We Are Doing Better

We define ourselves as a unique team, capable of blending our academic background with a global business mindset to bring the highest standard of quality and operational excellence into clinical research in Latin America.

Early Phase Trials

- First-in-Human Studies.
- Get to patients faster, no IND necessary.
- Valid data for FDA submission.

Rescue Studies

- Regain lost time and boost patient recruitment.
- We work alongside Global CROs to get studies back on track.
- More than 200 sites available.

Phase II & III Trials

- Full-Service Clinical Outsourcing.
- Proven infrastructure that can handle any trial.
- Local Regulatory Experts
- Wide network of sites and physicians.

Medical Devices

- A fast-track platform that will meet your timeline.
- We take care of everything, from shipping requirements all the way to data collection.
Pharmacovigilance Requirements in Brazil

Full Service CRO in LATAM

Outsourcing Clinical Trials to Latin America

Unlock the advantages and opportunities of outsourcing clinical trials to Latin America. Diverse patient population, streamlined regulations, and cost-effectiveness

Lower Operating Costs

From lower labor costs to lower costs for rent, utilities, and equipment, you can save money on your clinical trial budget while still ensuring the quality of your trial

Access to Emerging Markets

Latin America offers access to emerging markets, providing an opportunity for pharmaceutical companies to expand their reach and reach new patient populations.

Pharmacovigilance Requirements in Brazil

Cohortias is redefining Clinical Research in Latin America

We are committed to become leaders in providing clinical research services in Latin America. Here at Cohortias, we combine our academic roots, proven experience and a large pool of patients from an extensive network of sites.

Our main purpose is to deliver high quality data.

Pharmacovigilance Requirements in Brazil

Clinical Research in Latin America

Cohortias has built an extensive and highly reputable network of clinical sites which can access patients in a timely manner and operate within a standard-of-care comparable to the U.S. healthcare system.


  • Site Management

  • Data Management

  • Site Selection

  • Regulatory Submissions

  • Clinical Monitoring

  • Protocol Development


Beta Trials Platform

  • First-in-human studies

Medical Devices

  • Pilot and Pivotal Device Studies

Phases I – III

  • We partner with our clients to bring their products in a fast and efficient manner to the market with the highest quality standards


  • Diabetes/Metabolic Syndromes
  • Infectious Diseases
  • Cardiovascular
  • Neurology
  • Respiratory
  • Oncology

Pharmacovigilance Requirements in Brazil

Clinical Research in Latin America

Academic Leadership and Extensive Clinical Site Network for Efficient Clinical Trials

  • Our peer-to-peer management approach guarantees high patient recruitment and retention in any clinical trial

High Speed Execution

  • We offer the quickest start-up times in each country.
  • Efficient Clinical Site Selection and Contracting.
  • Benefit from our extensive network of clinical sites and streamlined contracting process.

Operational Excellence

  • Proven record of delivering rescue studies, we consistently exceed industry performance standards.
  • Our team provides efficient query resolution to keep your trial on track.

Business Insight and Flexibility

  • We offer innovative pricing models and short lines of communication to ensure maximum flexibility and cost-effectiveness.
  • At Cohortias, we prioritize  short lines of communication to ensure efficient collaboration.
  • Swift adaptation to changes in the trial landscape to keep your study on schedule.

Pharmacovigilance Requirements in Brazil

We provide our services with offices in:

Colombia &

Daniela Maresca
Daniela Maresca | Country Lead Argentina
Martín Hernández-Torre | CMO
Maritza Rojas | CRA II
Pedro Alvarez | Business Development Manager
Samantha Rodriguez Cohortias
Samantha Rdz. | Start-Up Manager
Pharmacovigilance Requirements in Brazil

The Cohortias Team

Pharmacovigilance Requirements in Brazil

As the largest South American Contract research Organization, we know the Advantages and Challenges Of the Region

Let Us Guide You Through The Latin American Clinical Research Landscape

Pharmacovigilance Requirements in Brazil

Network & Partnerships